{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:32:42Z","timestamp":1791084762736,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.vaccine.2009.04.062","type":"journal-article","created":{"date-parts":[[2009,5,28]],"date-time":"2009-05-28T09:02:18Z","timestamp":1243501338000},"page":"B13-B19","source":"Crossref","is-referenced-by-count":116,"special_numbering":"S2","title":["Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution"],"prefix":"10.1016","volume":"27","author":[{"given":"F.","family":"Marc LaForce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Ravenscroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoudou","family":"Djingarey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Viviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.04.062_bib1","series-title":"Abstract P225, 16th International Pathogenic Neisseria Conference","first-page":"283","article-title":"Socio economic study of meningitis epidemic impact in Burkina Faso","author":"Colombini","year":"2008"},{"issue":"Supplement","key":"10.1016\/j.vaccine.2009.04.062_bib2","first-page":"1","article-title":"La m\u00e9ningite c\u00e9r\u00e9bro-spinale en Afrique","volume":"28","author":"Lapeyssonnie","year":"1963","journal-title":"Bull World Health Organ"},{"issue":"4","key":"10.1016\/j.vaccine.2009.04.062_bib3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0035-9203(99)90106-2","article-title":"Meningococcal meningitis in Africa","volume":"93","author":"Greenwood","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.062_bib4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1365-3156.2006.01639.x","article-title":"100 years of epidemic meningitis in West Africa\u2014has anything changed?","volume":"11","author":"Greenwood","year":"2006","journal-title":"Trop Med Int Health"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.062_bib5","first-page":"499","article-title":"Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96","volume":"77","author":"Campagne","year":"1999","journal-title":"Bull World Health Org"},{"issue":"18","key":"10.1016\/j.vaccine.2009.04.062_bib6","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2009.04.062_bib7","first-page":"2849","article-title":"Studies on the meningococcal polysaccharides. I. Composition and chemical properties of the group A polysaccharide","volume":"246","author":"Liu","year":"1971","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.vaccine.2009.04.062_bib8","first-page":"2275","article-title":"Determination of the structure and conformation of bacterial polysaccharides by carbon 13 nuclear magnetic resonance. Studies on the group-specific antigens of Neisseria meningitidis serogroups A and X","volume":"249","author":"Bundle","year":"1974","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2009.04.062_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0008-6215(96)00253-4","article-title":"Full 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production","volume":"296","author":"Lemercinier","year":"1996","journal-title":"Carbohydr Res"},{"issue":"4","key":"10.1016\/j.vaccine.2009.04.062_bib10","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0731-7085(02)00462-4","article-title":"Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture","volume":"30","author":"Jones","year":"2002","journal-title":"J Pharm Biomed Anal"},{"issue":"7","key":"10.1016\/j.vaccine.2009.04.062_bib11","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1128\/IAI.70.7.3707-3713.2002","article-title":"Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses","volume":"70","author":"Berry","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2009.04.062_bib12","first-page":"123","article-title":"Production and control of Neisseria meningitidis vaccines","volume":"13","author":"Frasch","year":"1990","journal-title":"Adv Biotechnol Processes"},{"key":"10.1016\/j.vaccine.2009.04.062_bib13","unstructured":"WHO-WER. Intercountry meningitis meeting: preparing for the next epidemic seasons, Mali, October 2006. Wkly Epidemiol Rec 2007; 82(5):34\u201340."},{"key":"10.1016\/j.vaccine.2009.04.062_bib14","series-title":"Abstract P166, 16th International Pathogenic Neisseria Conference","first-page":"232","article-title":"A twenty year retrospective analysis of meningitis surveillance data from Burkina Faso, Mali and Niger","author":"Djingarey","year":"2008"},{"issue":"3","key":"10.1016\/j.vaccine.2009.04.062_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/14760584.5.3.319","article-title":"Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines","volume":"5","author":"Mueller","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2009.04.062_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1086\/426436","article-title":"Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing","volume":"40","author":"Parent du Ch\u00e2telet","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2009.04.062_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0035-9203(91)90337-X","article-title":"Clonal properties of meningococci from epidemic meningitis","volume":"85","author":"Achtman","year":"1991","journal-title":"Trans R SocTrop Med Hyg"},{"issue":"S","key":"10.1016\/j.vaccine.2009.04.062_bib18","doi-asserted-by":"crossref","first-page":"A8","DOI":"10.1016\/j.vaccine.2007.04.033","article-title":"Molecular surveillance of meningococcal meningitis in Africa","volume":"25","author":"Caugant","year":"2007","journal-title":"Vaccine"},{"issue":"7539","key":"10.1016\/j.vaccine.2009.04.062_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/bmj.38725.728472.BE","article-title":"Risk and protective factors for meningococcal disease in adolescents: matched cohort study","volume":"332","author":"Tully","year":"2006","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vaccine.2009.04.062_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197207062870102","article-title":"A simultaneous outbreak of meningococcal and influenza infections","volume":"287","author":"Young","year":"1972","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2009.04.062_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/infdis\/123.5.519","article-title":"Sero-epidemiologic studies of meningococcal infection with the indirect hemagglutination test","volume":"123","author":"Eickhoff","year":"1971","journal-title":"J Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2009.04.062_bib22","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1001\/jama.1967.03130130030008","article-title":"Acute respiratory disease and meningococcal infection in army recruits","volume":"201","author":"Artenstein","year":"1967","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.vaccine.2009.04.062_bib23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(07)70288-8","article-title":"Meningococcal carriage in the African meningitis belt","volume":"7","author":"Trotter","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2009.04.062_bib24","article-title":"Fondation M\u00e9rieux. [Etude longitudinale du portage rhino-pharyng\u00e9 de m\u00e9ningocoques dans un village voltaique]. Meeting report. [R\u00e9union sur la standardisation des vaccins m\u00e9ningitiques]","author":"Etienne","year":"1975","journal-title":"Fondation M\u00e9rieux"},{"issue":"6","key":"10.1016\/j.vaccine.2009.04.062_bib25","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1086\/500511","article-title":"Neisseria meningitidis serogroups A and W-135: carriage and immunity in Burkina Faso, 2003","volume":"193","author":"Mueller","year":"2006","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2009.04.062_bib26","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.1990.03450100061026","article-title":"Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis","volume":"264","author":"Moore","year":"1990","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2009.04.062_bib27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00005792-198409000-00001","article-title":"Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency","volume":"63","author":"Ross","year":"1984","journal-title":"Medicine (Baltimore)"},{"issue":"16","key":"10.1016\/j.vaccine.2009.04.062_bib28","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM198304213081601","article-title":"Prevalence of congenital or acquired complement deficiency in patients with sporadic meningococcal disease","volume":"308","author":"Ellison","year":"1983","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.062_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2249.2000.01113.x","article-title":"High prevalence of complement component C6 deficiency among African Americans in the southeastern USA","volume":"119","author":"Zhu","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2009.04.062_bib30","unstructured":"WHO. Control of epidemic meningococcal disease. WHO practical guidelines (WHO\/EMC\/BAC\/98.3) [Lutte contre les \u00e9pid\u00e9mies de m\u00e9ningite \u00e0 m\u00e9ningocoque. Guide pratique OMS, 2\u00e8me \u00e9dition]. 2nd ed. Geneva: World Health Organization; 1998."},{"issue":"38","key":"10.1016\/j.vaccine.2009.04.062_bib31","first-page":"306","article-title":"Detecting meningococcal meningitis epidemics in highly-endemic African countries","volume":"75","year":"2000","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2009.04.062_bib32","unstructured":"WHO. WHO strategy for prevention and control of meningococcal disease in Africa. 1\u201317. WHO; 2001."},{"issue":"6123","key":"10.1016\/j.vaccine.2009.04.062_bib33","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/bmj.1.6123.1317","article-title":"Prevention of secondary cases of meningococcal disease in household contacts by vaccination","volume":"1","author":"Greenwood","year":"1978","journal-title":"BMJ"},{"issue":"40","key":"10.1016\/j.vaccine.2009.04.062_bib34","first-page":"331","article-title":"Position Paper: meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines","volume":"77","author":"WHO","year":"2002","journal-title":"Wkly Epidemiol Rec"},{"issue":"4","key":"10.1016\/j.vaccine.2009.04.062_bib35","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1203\/00006450-199210000-00002","article-title":"Rational design of conjugate vaccines","volume":"32","author":"Dintzis","year":"1992","journal-title":"Pediatr Res"},{"key":"10.1016\/j.vaccine.2009.04.062_bib36","series-title":"Development and clinical uses of haemophilus b conjugate vaccines","first-page":"37","article-title":"Conjugation: design, chemistry and analysis","author":"Knistern","year":"1994"},{"issue":"3","key":"10.1016\/j.vaccine.2009.04.062_bib37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.vaccine.2009.04.062_bib38","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1086\/344324","article-title":"Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom","volume":"186","author":"Borrow","year":"2002","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2009.04.062_bib39","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.062_bib40","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/CMR.13.2.302-317.2000","article-title":"Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates","volume":"13","author":"Peltola","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2009.04.062_bib41","unstructured":"Progress toward eliminating Haemophilus influenzae type b disease among infants and children. United States, 1987\u20131997. MMWR 1998; 47(46):993\u20138."},{"issue":"9480","key":"10.1016\/j.vaccine.2009.04.062_bib42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(05)66788-8","article-title":"Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study","volume":"366","author":"Adegbola","year":"2005","journal-title":"Lancet"},{"issue":"9431","key":"10.1016\/j.vaccine.2009.04.062_bib43","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.vaccine.2009.04.062_bib44","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1001\/jama.292.20.2491","article-title":"Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine","volume":"292","author":"De Wals","year":"2004","journal-title":"JAMA"},{"issue":"32","key":"10.1016\/j.vaccine.2009.04.062_bib45","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.vaccine.2005.03.045","article-title":"Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain","volume":"23","author":"Larrauri","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.04.062_bib46","unstructured":"Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR--9):1\u201335."},{"issue":"16","key":"10.1016\/j.vaccine.2009.04.062_bib47","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","article-title":"Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine","volume":"294","author":"Lexau","year":"2005","journal-title":"JAMA"},{"issue":"12 Suppl.","key":"10.1016\/j.vaccine.2009.04.062_bib48","first-page":"S274","article-title":"Global epidemiology of meningococcal disease and vaccine efficacy","volume":"23","author":"Pollard","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2009.04.062_bib49","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1016\/S0264-410X(99)00139-5","article-title":"Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood","volume":"17","author":"MacLennan","year":"1999","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2009.04.062_bib50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/00006454-200002000-00013","article-title":"Safety and immunogenicity of three doses of a Neisseria meningitidis A+C diphtheria conjugate vaccine in infants from Niger","volume":"19","author":"Campagne","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"9372","key":"10.1016\/j.vaccine.2009.04.062_bib51","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/S0140-6736(03)13494-0","article-title":"Meningococcal conjugate vaccines for Africa: a model for the development of new vaccines for poorest countries","volume":"361","author":"J\u00f3dar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2009.04.062_bib52","series-title":"Abstract P8.3.09. 15th International Pathogenic Neisseria Conference","first-page":"119","article-title":"The application of physicochemical methods of analysis to the development of conjugate vaccines against meningococcal group A bacteria","author":"Ravenscroft","year":"2006"},{"key":"10.1016\/j.vaccine.2009.04.062_bib53","series-title":"Abstract P101. 16th International Pathogenic Neisseria Conference","first-page":"171","article-title":"Physicochemical and immunological characterization of the drug product (final lot) of a meningococcal group A conjugate vaccine","author":"Ravenscroft","year":"2008"},{"issue":"Supplement 1","key":"10.1016\/j.vaccine.2009.04.062_bib54","doi-asserted-by":"crossref","first-page":"A101","DOI":"10.1016\/j.vaccine.2007.04.050","article-title":"Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults","volume":"25","author":"Kshirsagar","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.04.062_bib55","series-title":"Abstract P211. 16th International Pathogenic Neisseria Conference","first-page":"269","article-title":"A Phase II, observer-blind, randomized, controlled study to evaluate the safety, immunogenicity, and memory of a booster dose of a meningococcal A conjugate vaccine (MenAfriVacTM) in healthy African children","author":"Okoko","year":"2008"},{"key":"10.1016\/j.vaccine.2009.04.062_bib56","series-title":"Abstract P134. 16th International Pathogenic Neisseria Conference","first-page":"202","article-title":"Safety and immunogenicity od a new meningococcal A conjugate vaccine in a health African population aged 2-29 years","author":"Diallo","year":"2008"},{"key":"10.1016\/j.vaccine.2009.04.062_bib57","series-title":"Abstract P223. 16th International Pathogenic Neisseria Conference","first-page":"281","article-title":"Human complement bactericidal activity following vaccination in a phase 2 safety and immunogenicity study of a new meningococcal A conjugate vaccine in healthy African toddlers","author":"Bash","year":"2008"},{"issue":"7385","key":"10.1016\/j.vaccine.2009.04.062_bib58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.vaccine.2009.04.062_bib59","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2009.04.062_bib60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands","volume":"25","author":"de Greeff","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2009.04.062_bib61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/aje\/kwi160","article-title":"Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination","volume":"162","author":"Trotter","year":"2005","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2009.04.062_bib62","doi-asserted-by":"crossref","unstructured":"Suraratdecha C, Levin C, LaForce FM. Disease burden from group A Neisseria meningitidis in hyperendemic countries of the African meningitis belt. In Preedy RV, Watson RR, editors. Handbook of Disease Burdens and Quality of Life Measures. New York: Springer; 2009, in press.","DOI":"10.1007\/978-0-387-78665-0_75"},{"key":"10.1016\/j.vaccine.2009.04.062_bib63","unstructured":"LaForce, FM. Introduction of a Group A meningococcal conjugate vaccine in sub-Saharan Africa: Cost\/savings analysis. MVP report; 2008."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09006161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09006161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T11:31:14Z","timestamp":1558351874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09006161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":63,"alternative-id":["S0264410X09006161"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.04.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}